Spark Therapeutics Inc (NASDAQ:ONCE) – Research analysts at Wedbush reduced their Q1 2018 EPS estimates for shares of Spark Therapeutics in a research note issued to investors on Tuesday. Wedbush analyst D. Nierengarten now anticipates that the biotechnology company will post earnings per share of ($1.88) for the quarter, down from their prior estimate of ($1.80). Wedbush has a “Underperform” rating and a $35.00 price objective on the stock. Wedbush also issued estimates for Spark Therapeutics’ Q2 2018 earnings at ($1.88) EPS, Q3 2018 earnings at ($1.90) EPS, Q4 2018 earnings at ($1.92) EPS, FY2018 earnings at ($7.57) EPS, FY2019 earnings at ($6.59) EPS, FY2020 earnings at ($5.62) EPS, FY2021 earnings at ($4.60) EPS and FY2022 earnings at ($3.22) EPS.
ONCE has been the topic of a number of other research reports. Jefferies Group reaffirmed a “buy” rating and set a $95.00 target price on shares of Spark Therapeutics in a report on Tuesday, October 10th. SunTrust Banks set a $101.00 price target on shares of Spark Therapeutics and gave the stock a “buy” rating in a report on Monday, October 16th. BMO Capital Markets reissued a “buy” rating and issued a $101.00 price target on shares of Spark Therapeutics in a report on Wednesday, November 15th. Cowen reissued a “buy” rating and issued a $95.00 price target on shares of Spark Therapeutics in a report on Tuesday, October 10th. Finally, Royal Bank of Canada decreased their price target on shares of Spark Therapeutics from $100.00 to $98.00 and set an “outperform” rating on the stock in a report on Wednesday, November 8th. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the stock. Spark Therapeutics currently has an average rating of “Buy” and a consensus target price of $74.45.
Shares of Spark Therapeutics (NASDAQ ONCE) opened at $51.26 on Thursday. The firm has a market cap of $1,870.63, a P/E ratio of -7.10 and a beta of 3.14. Spark Therapeutics has a twelve month low of $41.06 and a twelve month high of $91.75.
Spark Therapeutics (NASDAQ:ONCE) last posted its earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.11). The firm had revenue of $1.90 million for the quarter, compared to the consensus estimate of $1.40 million. Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The business’s revenue was up 45.8% on a year-over-year basis. During the same period last year, the company posted ($1.07) EPS.
Several hedge funds have recently added to or reduced their stakes in ONCE. Ameritas Investment Partners Inc. grew its holdings in shares of Spark Therapeutics by 23.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 389 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Spark Therapeutics during the 2nd quarter valued at $143,000. BNP Paribas Arbitrage SA grew its holdings in shares of Spark Therapeutics by 530.1% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock valued at $174,000 after purchasing an additional 2,449 shares during the last quarter. Teacher Retirement System of Texas bought a new position in shares of Spark Therapeutics during the 3rd quarter valued at $225,000. Finally, Prudential Financial Inc. bought a new position in shares of Spark Therapeutics during the 3rd quarter valued at $239,000. 94.91% of the stock is currently owned by institutional investors.
In related news, insider Daniel Faga sold 7,500 shares of the stock in a transaction on Tuesday, October 24th. The shares were sold at an average price of $80.96, for a total transaction of $607,200.00. Following the transaction, the insider now owns 6,000 shares of the company’s stock, valued at approximately $485,760. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Katherine A. High sold 5,000 shares of the stock in a transaction on Tuesday, October 31st. The shares were sold at an average price of $83.30, for a total transaction of $416,500.00. Following the transaction, the insider now directly owns 215,000 shares in the company, valued at approximately $17,909,500. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 56,309 shares of company stock worth $4,141,385. 7.30% of the stock is owned by insiders.
ILLEGAL ACTIVITY NOTICE: This story was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/20/q1-2018-eps-estimates-for-spark-therapeutics-inc-once-cut-by-wedbush.html.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.